Sugimoto E - Search Results

1

Psoriasis treatment and biologic switching: The association with clinical characteristics and laboratory biomarkers over a 13-year retrospective study.

Koyama A, Li L, Yamamoto T, Taira H, Sugimoto E, Ito Y, Mizuno Y, Awaji K, Tateishi S, Kanda H, Sato S, Shibata S. Koyama A, et al. Among authors: sugimoto e. J Dermatol. 2024 Dec;51(12):1572-1578. doi: 10.1111/1346-8138.17465. Epub 2024 Sep 13. J Dermatol. 2024. PMID: 39269210 Free PMC article.

2

Impact of Pretreatment Systemic Inflammatory Markers on Treatment Persistence with Biologics and Conventional Systemic Therapy: A Retrospective Study of Patients with Psoriasis Vulgaris and Psoriatic Arthritis.

Sugimoto E, Matsuda H, Shibata S, Mizuno Y, Koyama A, Li L, Taira H, Ito Y, Awaji K, Yamashita T, Sato S. Sugimoto E, et al. J Clin Med. 2023 Apr 21;12(8):3046. doi: 10.3390/jcm12083046. J Clin Med. 2023. PMID: 37109382 Free PMC article.

3

Elevated serum vasohibin-1 levels in atopic dermatitis: Implications for disease chronicity.

Taira H, Ito Y, Yamamoto T, Koyama A, Li L, Sugimoto E, Mizuno Y, Awaji K, Sato S, Shibata S. Taira H, et al. Among authors: sugimoto e. J Dermatol. 2024 Dec;51(12):1685-1689. doi: 10.1111/1346-8138.17259. Epub 2024 May 6. J Dermatol. 2024. PMID: 38711287

4

Prevalence of antiphospholipid autoantibodies associated with biologics treatment for psoriasis.

Li L, Toyama S, Mizuno Y, Yamamoto T, Hiroshima A, Koyama A, Taira H, Sugimoto E, Ito Y, Awaji K, Tateishi S, Kanda H, Asano Y, Sato S, Shibata S. Li L, et al. Among authors: sugimoto e. Sci Rep. 2024 Jul 10;14(1):15975. doi: 10.1038/s41598-024-65378-6. Sci Rep. 2024. PMID: 38987260 Free PMC article.

5

Interleukin-26-DNA complexes promote inflammation and dermal-epidermal separation in a modified human cryosection model of bullous pemphigoid.

Mizuno Y, Shibata S, Ito Y, Taira H, Sugimoto E, Awaji K, Sato S. Mizuno Y, et al. Among authors: sugimoto e. Front Immunol. 2022 Oct 10;13:1013382. doi: 10.3389/fimmu.2022.1013382. eCollection 2022. Front Immunol. 2022. PMID: 36311716 Free PMC article.

6

Reliability, validity, and sensitivity of the Japanese version of the University of California Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument: Application to efficacy assessment of intravenous immunoglobulin administration.

Matsuda KM, Sugimoto E, Ako Y, Kitamura M, Miyahara M, Kotani H, Norimatsu Y, Hisamoto T, Kuzumi A, Fukasawa T, Sato S, Yoshizaki A. Matsuda KM, et al. Among authors: sugimoto e. J Dermatol. 2024 Jun;51(6):741-751. doi: 10.1111/1346-8138.17202. Epub 2024 Apr 1. J Dermatol. 2024. PMID: 38558171 Free PMC article.

7

Pigmented circumscribed plantar hypokeratosis mimicking acral lentiginous melanoma: A case report.

Ohkuma K, Yoshino K, Morita H, Sugimoto E, Hiura A, Uehara J, Fujisawa Y. Ohkuma K, et al. Among authors: sugimoto e. J Dermatol. 2021 Feb;48(2):e108-e109. doi: 10.1111/1346-8138.15715. Epub 2020 Dec 2. J Dermatol. 2021. PMID: 33617012 No abstract available.

8

SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation.

Chang YH, Yamamoto K, Fujino T, Wang TW, Sugimoto E, Zhang W, Yabushita T, Suzaki K, Pietsch EC, Weir BA, Crescenzo R, Cowley GS, Attar R, Philippar U, Wunderlich M, Mizukawa B, Zheng Y, Enomoto Y, Imai Y, Kitamura T, Goyama S. Chang YH, et al. Among authors: sugimoto e. Cell Rep. 2024 Aug 27;43(8):114536. doi: 10.1016/j.celrep.2024.114536. Epub 2024 Aug 2. Cell Rep. 2024. PMID: 39096901 Free article.

9

Hyperactive Natural Killer cells in Rag2 knockout mice inhibit the development of acute myeloid leukemia.

Sugimoto E, Li J, Hayashi Y, Iida K, Asada S, Fukushima T, Tamura M, Shikata S, Zhang W, Yamamoto K, Kawabata KC, Kawase T, Saito T, Yoshida T, Yamazaki S, Kaito Y, Imai Y, Denda T, Ota Y, Fukuyama T, Tanaka Y, Enomoto Y, Kitamura T, Goyama S. Sugimoto E, et al. Commun Biol. 2023 Dec 21;6(1):1294. doi: 10.1038/s42003-023-05606-3. Commun Biol. 2023. PMID: 38129572 Free PMC article.

10

Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia.

Kaito Y, Sugimoto E, Nakamura F, Tsukune Y, Sasaki M, Yui S, Yamaguchi H, Goyama S, Nannya Y, Mitani K, Tamura H, Imai Y. Kaito Y, et al. Among authors: sugimoto e. Haematologica. 2024 Apr 1;109(4):1107-1120. doi: 10.3324/haematol.2023.282915. Haematologica. 2024. PMID: 37731380 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

164 results

Search Page

Filters